AIBN Associate Professor Joy Wolfram believes decoding a cellular messaging system will give them the upper hand against a particularly deadly type of breast cancer.
AIBN researcher Dr Nick Fletcher has won an Advance Queensland Industry Research Fellowship to explore localised cell death and the immune response to cancer.
What can the metabolism of 606 people from China, the Netherlands and Australia tell us about the onset and progression of ALS? Turns out, quite a bit.
For three months Tahmina Tabassum relearned what she knew about industry and entrepreneurship during a placement with biotech Azafaros BV, a whirlwind experience that included a stint at the company’s headquarters in Basel.
A University of Queensland (UQ) developed antiviral surface coating that protects against COVID-19 and other existing and emerging viral and bacterial transmissions is being tested on the International Space Station.
AIBN researchers want HIV patients to have the option of taking a long-acting antiretroviral dose once a week, instead of having to take a dose every day.
The gold standard test for oesophageal cancer involves a tube being stuck down your throat. PhD scholar Ramlah Khamis is working on a better method that could, in turn, help lift survival rates.
From environmental and energy technologies to biofuels, organoids, and new platforms for vaccines and therapeutics, here’s a wrap of the AIBN's biggest moments from the past 12 months – and some exciting developments we’re looking forward to in 2024.
Researcher Jacob Earnshaw has joined the growing list of AIBN PhD scholars to embark on a UQ Startup AdVenture. This is what he picked up during his time in Singapore's busting entrepreneurial scene.
AIBN researchers are using synthetic brain organoid models, grown in a laboratory from human stem cells, to find new ways to rejuvenate brains that have been prematurely aged by COVID-19.
Two exciting AIBN projects have scored new funding to help industry collaborators crack the lucrative computer chip industry and capitalise on opportunities in waste-to-catalyst conversion
In 2023, a cure for ALS remains elusive, and there are still no treatments to reverse its effects. But AIBN researchers are piecing together information that could get us there.
Four AIBN-led projects have been recognised in latest round of the $220 million Australian Research Council Discovery scheme, a program that recognises research with economic, commercial, environmental, social and/or cultural benefits.